Kerendia (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist (MRA) approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney failure, cardiovascular death, heart attack, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).